NCT03689192 · REGISTRY CONDITION SEARCH

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1
Status at capture: COMPLETED
Registry last update: 2023-02-28

In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors. Patients will be treated with an ARG1 vaccine every third week for 45 weeks.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Adverse Events Evaluated by CTCAE 4.0

→

outcome · POSTED

Immune Responses

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

4.Progression Free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Age ≥ 18 2. The patient has metastatic solid tumors (NSCLC, colorectal cancer, urothelial cancer, breast cancer, ovarian cancer, malignant melanoma or HNSCC); progressive or recurrent disease on or following treatment with standard of care agents 3. At least one measurable parameter according to RECIST 1.1. 4. The patient has an ECOG performance status of 0 or 1 5. Life expectancy of at least 3 months 6. Prior PD1/PD-L1 allowed 7. The patient is a female of childbearing potential with negative pregnancy test 8. For fertile women: Agreement to use contraceptive methods with a failure rate of \< 1 % per year during the treatment period and for at least 150 days 12 weeks after the treatment. Safe contraceptive methods for women are birth control pills, intrauterine device, contraceptive injection, contraceptive implant, contraceptive patch or contraceptive vaginal ring. 9. For men: Agreement to use contraceptive measures and agreement to refrain from donating sperm 10. The patient has met the following hematological and biochemical criteria: 1. AST and ALT ≤2,5 X ULN or ≤5 X ULN with liver metastases 2. Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level \> 1,5 ULN 3. Serum creatinine ≤1,5 X ULN 4. ANC (Absolute Neutrophil Count) ≥1,000/mcL 5. Platelets ≥ 75,000 /mcL 6. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L 11. Mandatory provision of archival tissue and blood for biomarker testing at baseline 12. Mandatory provision of blood for biomarker testing during the study 13. Signed declaration of consent after oral and written information about the protocol Exclusion Criteria: 1. The patient has not recovered from surgery or is less than 4 weeks from major surgery 2. The patient has a history of life-threatening or severe immune related adverse events on treatment with another immunotherapy and is considered to be at risk of not recovering 3. The patient is expected to require any other form of systemic antineoplastic therapy or radiation therapy while receiving the treatment. However, radiation therapy treatment of non target lesion is allowed. 4. The patient has a history of severe clinical autoimmune disease 5. The patient has a history of pneumonitis, organ transplant, human immunodeficiency virus positive, active hepatitis B or hepatitis C 6. The patient requires systemic steroids for management of immune-related adverse events experienced on another immunotherapy 7. The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders) 8. The patient is pregnant or breastfeeding 9. The patient is unable to voluntarily agree to participate by signed informed consent or assent 10. The patient has an active infection requiring systemic therapy 11. The patient has received a live virus vaccine within 30 days of planned start of therapy 12. Significant medical disorder according to investigator; e.g. severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus 13. Concurrent treatment with other experimental drugs 14. Concurrent treatment with Valproate or Xanthin Oxidase inhibitors 15. Known side effects to Montanide ISA-51 16. Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc. 17. Severe allergy or anaphylactic reactions earlier in life
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
One ARG1-vaccine every third week for 45 weeks.
intervention Names
Biological: ARG1-18,19,20
label
ARG1-18,19,20 peptide vaccine
type
EXPERIMENTAL

interventions

arm Group Labels
ARG1-18,19,20 peptide vaccine
description
300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
name
ARG1-18,19,20
type
BIOLOGICAL

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 13
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Patients were evaluated according to Common Terminology Criteria for Adverse Events (CTCEA). An adverse event (AE) is an abnormal clinical finding. Each participant was assessed from start of treatment until 6 months after the last vaccine.
measure
Adverse Events Evaluated by CTCAE 4.0
time Frame
0 - 75 weeks

secondary Outcomes

description
To evaluate the immunological impact of the ARG1-18,19,20 peptide vaccines using blood samples and tumor biopsies.
measure
Immune Responses
time Frame
project blood samples were taken at baseline and every 3 months for a maximum of 1,5 year. Tumor biopsies were taken at baseline and after 3 months if possible.
description
Overall Survival (OS) defined as time from treatment initiation to death, will be described with use of Kaplan Meier curve.
measure
Overall Survival
time Frame
0 - 75 weeks
description
Progression free survival (PFS) defined as the time from treatment initiation to disease progression, relapse or death due to any cause, which ever comes first, will be described with Kaplan Meier curve. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
measure
4.Progression Free Survival
time Frame
0 - 75 weeks

Full study description

brief Summary: In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors. Patients will be treated with an ARG1 vaccine every third week for 45 weeks.
detailed Description: Arginase-1 (ARG1) is an enzyme that converts the amino acid arginine into urea and ornithine. ARG1 is mainly expressed in hepatocytes but different myeloid cells are also capable of ARG1-expression. An ARG1-induced arginine depletion suppresses T cell function through the impairment of the T cell receptor (TCR)-complex. A research group from the Center for Cancer Immune Therapy (CCIT) have identified spontaneous T cell reactivity against ARG1 peptides in peripheral blood mononuclear cells of cancer patients and healthy donors. The theoretic background for an ARG1 peptide vaccine is to activate ARG1-specific T cells to infiltrate the tumor microenvironment and eliminate ARG1-expressing immunosuppressive cells. The aim is to treat 10 patients with progressive solid tumors following treatment with standard of care agents. Patients will receive ARG1 vaccinations administered subcutaneously every third week for 45 weeks. The primary endpoint is to evaluate safety and toxicity. Immune responses will be assessed using blood- and tumor tissue samples and clinical responses are evaluated using RECIST 1.1.

Source references

references

citation
Lorentzen CL, Martinenaite E, Kjeldsen JW, Holmstroem RB, Mork SK, Pedersen AW, Ehrnrooth E, Andersen MH, Svane IM. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial. Front Immunol. 2022 Oct 17;13:1023023. doi: 10.3389/fimmu.2022.1023023. eCollection 2022.
pmid
36330525
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-8e438333a828cf64f284
requested nct id
NCT03689192
primary nct id
NCT03689192
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
payload sha256
485336443cc7e62247256650180f4d7a3e5791ee0953f5e9736bdc729c02d1e4
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-8e438333a828cf64f284
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT03689192
occurrences
context exact
NCT03689192
end
11
exact text
NCT03689192
start
0
offset unit
unicode_code_points
query cond
Small Intestine Cancer
query disease state id
ds-small-intestine-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
source json pointer
/studies/92/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
e56d257aabc10f7b7c049c27da058aa9b25d45768788a1ca71a365993fe9b13c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-8faeb09c996681ebab1f
requested nct id
NCT03689192
primary nct id
NCT03689192
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Ovarian+Germ+Cell+Tumors&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
payload sha256
ae58e45a32bd0f8864dc8e9244c02e9ce25a28c070e273b6cc844c4245198441
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-8faeb09c996681ebab1f
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT03689192
occurrences
context exact
NCT03689192
end
11
exact text
NCT03689192
start
0
offset unit
unicode_code_points
query cond
Ovarian Germ Cell Tumors
query disease state id
ds-ovarian-germ-cell-tumors
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-ovarian-germ-cell-tumors-000.json
source file sha256
359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
source json pointer
/studies/63/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
e56d257aabc10f7b7c049c27da058aa9b25d45768788a1ca71a365993fe9b13c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Ovarian+Germ+Cell+Tumors&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice